MR imaging enhancement with superparamagnetic iron oxide in chronic liver disease: Influence of liver dysfunction and parenchymal pathology

Abdominal Imaging

Volumn 21, Issue 4, 1996, Pages 318-323

  Yamashita, Y ^a   Yamamoto, H ^a   Hirai, A ^a   Yoshimatsu, S ^a   Baba, Y ^a   Takahashi, M ^a  

^a KUMAMOTO UNIVERSITY   (Japan)

Author keywords

Liver cirrhosis, hepatocellular carcinoma; MR imaging, contrast agent; Superparamagnetic iron oxide

Indexed keywords

ALBUMIN; ASPARTATE AMINOTRANSFERASE; BILIRUBIN; INDOCYANINE GREEN; SUPERPARAMAGNETIC IRON OXIDE;

ADULT; AGED; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; CHRONIC HEPATITIS; CHRONIC LIVER DISEASE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTRAST ENHANCEMENT; DRUG UPTAKE; FEMALE; HUMAN; HUMAN TISSUE; LIVER BIOPSY; LIVER CELL CARCINOMA; LIVER CIRRHOSIS; LIVER PARENCHYMA; MALE; NUCLEAR MAGNETIC RESONANCE IMAGING; PHASE 2 CLINICAL TRIAL; PHASE 3 CLINICAL TRIAL; PRIORITY JOURNAL;

ADULT; AGED; ASPARTATE AMINOTRANSFERASES; BILIRUBIN; BIOPSY; CARCINOMA, HEPATOCELLULAR; CHRONIC DISEASE; COLORING AGENTS; CONTRAST MEDIA; FEMALE; FERROSOFERRIC OXIDE; HEPATITIS; HUMANS; IMAGE ENHANCEMENT; INDOCYANINE GREEN; IRON; LIVER; LIVER CIRRHOSIS; LIVER DISEASES; LIVER NEOPLASMS; MAGNETIC RESONANCE IMAGING; MALE; MIDDLE AGED; OXIDES; SERUM ALBUMIN; SPLEEN;

EID: 0029979786     PISSN: 09428925     EISSN: None     Source Type: Journal    
DOI: 10.1007/s002619900072     Document Type: Article

References (12)

1. Fretz CJ, Stark DD, Metz CE, et al. Detection of hepatic metastases: comparison of contrast-enhanced CT, unenhanced MR imaging, and iron oxide-enhanced MR imaging. AJR 1990;155:763-770
2. Tsang YM, Stark DD, Chen MC, et al. Hepatic micrometastasis in the rats: ferrite-enhanced MR imaging. Radiology 1988;167:21-24
3. Stark DD, Weissleder R, Elizondo G, et al Superparamagnetic iron oxide: clinical application as a contrast agent for MR imaging of the liver. Radiology 1988;168:297-301
4. Elizondo G, Weissleder R, Stark DD, et al. Hepatic cirrhosis and hepatitis: MR imaging enhanced with superparamagnetic iron oxide. Radiology 1990;174:797-801
5. Reimer P, Weissleder R, Lee AS, et al. Asialoglycoprotein receptor function in benign liver disease: evaluation with MR imaging. Radiology 1991;178:769-774
6. Clement O, Frija G, Chambon C, et al. Liver tumors in cirrhosis: experimental study with SPIO-enhanced MR imaging. Radiology 1991;180:31-36
7. Pugh RN, Murray-Lyon IM, Dawson JL. Transection of oesophageus for bleeding oesophageal varices. Br J Surg 1973;60:646-649
8. Ferrucci JT, Stark DD. Iron oxide-enhanced MR imaging of the liver and spleen: review of the first 5 years. AJR 1990;155:943-960
9. Triger DR. Evaluation of liver disease by radionuclide scanning. In: Zakim D, Boyer TD, eds. Hepatology: a text book of liver disease, vol. 1, 2nd ed. Philadelphia: WB Saunders, 1990:689-700
10. Tanimoto A, Kreft BP, Baba Y, et al. Evaluation of hepatocyte-specific paramagnetic contrast media for MR imaging of hepatitis. JMRI 1993;3:786-793
11. Waxman AD. Scintigraphic evaluation of diffuse hepatic disease. Semin Nucl Med 1982;12:75-88
12. DeNardo SJ, Bell GB, DeNardo GL, et al. Diagnosis of cirrhosis and hepatitis by quantitative hepatic and other reticuloendothelial clearance rates. J Nucl Med 1976;17:449-459